Malathion clinical trials
How each study uses Malathion is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 2 Aug 1982 · OVIDE · NDA 018613 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Malathion gel 0.5%
- 3
Studies by the year they started
4 studies that test it; most in 2009 (3)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Related medicines
As reviewed, each with the page that says it.
- One of Cholinesterase inhibitors source
Studies
Open first, then newest update. How each study uses Malathion is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head LiceCompletedPhase 2/3Taro Pharmaceuticals USANCT00752973Written as MALG (malathion) Treatment
- Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head LiceCompletedPhase 3Taro Pharmaceuticals USANCT00927472Written as Malathion gel 0.5%
- Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head LiceCompletedPhase 3Taro Pharmaceuticals USANCT00963508Written as Malathion gel 0.5%
- Pharmacokinetics of Malathion Gel 0.5% and Malathion 0.5% Lotion (Ovide) in Patients With Head LiceCompletedPhase 1Taro Pharmaceuticals USANCT00927407Written as Malathion gel 0.5%
As the comparator · 2 — what is tested is compared with Malathion
- Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head LiceCompletedPhase 3Taro Pharmaceuticals USANCT00244439Written as Ovide (malathion) lotion 0.05%
- Ivermectin in the Treatment of Head LiceCompletedPhase 3Johnson & Johnson Consumer and Personal Products WorldwideNCT00819520Written as malathion
Codes
What other systems call Malathion · ClinicalTrials.gg INT007762
- MeSH (NLM) D008294MalathionConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) U5N7SU872WMALATHIONConfirmed FDA, NLM, Wikidata
- RxNorm 6606Confirmed FDA, Wikidata
- Wikidata Q423005malathionConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C47593MalathionOne source FDA
- DrugBank DB00772One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D008294 | Malathion | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | U5N7SU872W | MALATHION | Confirmed FDA, NLM, Wikidata |
| RxNorm | 6606 | — | Confirmed FDA, Wikidata |
| Wikidata | Q423005 | malathion | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C47593 | Malathion | One source FDA |
| DrugBank | DB00772 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.